Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

Iron deficiency without anemia is a common feature of moderate-to-severe atopic dermatitis (AD), according to a study published in Nutrients. A recently approved injectable eczema drug provides quick ...

Delayed remission with advanced therapies in IBD is not associated with worse 1-year clinical or endoscopic outcomes.

A new analysis highlights differential long-term drug survival of commonly used biologics in psoriasis to guide treatment ...

A real world systematic review and meta-analysis found tildrakizumab improved plaque psoriasis severity and quality of life ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and greater patient access to advanced therapies. The shift from conventional ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...

Khaberni - A medical study has revealed promising results in treating moderate to severe psoriasis, one of the most ...

Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

The most common approaches to treating acute promyelocytic leukemia (APL) in adults are described here. To learn how children with APL are treated, see here. Prompt diagnosis and treatment of acute ...

Spyre Therapeutics (SYRE) stock analysis: de-risked pipeline, cash runway to H2 2028, and 2026–2027 Phase 2 catalysts in ...

Treatment is not a one size fits all approach. Where you go for mental health treatment depends on your situation and recovery needs. Knowing where to look and what to expect can help reduce confusion ...